Gene therapy biotech AveXis raised $65 million in Series D cash to advance a potential one-time treatment for the rare spinal muscular atrophy, a debilitating disease with no approved therapies. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback